The cost of improving drug safety in Europe
This article was originally published in Scrip
Executive Summary
The need to ensure that medicines have a positive benefit-risk profile, both before marketing approval and throughout their lifecycle, has become an accepted tenet of pharmaceutical development and regulation. It is in no one's interest to have drugs on the market that do more harm than good.